Back to top
more

Novartis (NVS)

(Real Time Quote from BATS)

$118.69 USD

118.69
529,903

+0.19 (0.16%)

Updated Sep 4, 2024 12:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (61 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Intercept (ICPT) Gains 7.5% YTD on Progress in NASH Space

by Zacks Equity Research

Intercept (ICPT) stock gains as it becomes the forerunner in the NASH drug race.

Global Blood's (GBT) Oxbryta Secures FDA Approval for SCD

by Zacks Equity Research

Global Blood's (GBT) Oxbryta wins the FDA nod to address sickle cell disease in patients aged 12 years and above. The approval comes three months ahead of schedule.

Sweta Jaiswal, FRM headshot

Why Biotech ETFs Surged in Monday's Trading Session

by Sweta Jaiswal, FRM

Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to drive the biotech market.

Kinjel Shah headshot

4 Big Drug Stocks Ripe for Takeover After NVS-MDCO Deal

by Kinjel Shah

Here are four stocks that boast promising prospects and are most likely to be takeout targets.

Roche's NDA for SMA Drug Risdiplam Gets Priority Review

by Zacks Equity Research

The FDA accepts Roche's (RHHBY) NDA for risdiplam under a priority review to treat spinal muscular atrophy. A verdict is pending on May 24, 2020.

A Day of Mergers: TIF, AMTD, MDCO & More

by Zacks Equity Research

A Day of Mergers: TIF, AMTD, MDCO & More

Mark Vickery headshot

Biggest Merger Monday in Awhile: TIF, AMTD, MDCO & More

by Mark Vickery

While Tiffany's agrees to terms with French luxury brand LVMH, Schwab buys Ameritrade, Novartis takes Medicines Co. and more.

Novartis (NVS) to Acquire The Medicines Company for $9.7B

by Zacks Equity Research

Novartis (NVS) set to acquire The Medicines Company and add a promising candidate to its cardiovascular pipeline.

The Medicines Company to be Acquired by Novartis for $9.7B

by Zacks Equity Research

The Medicines Company (MDCO) agrees to the $85 per share or $9.7-billion acquisition offer from Novartis.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod to NVS' & AZN's Drugs, BMY-CELG Merger Closes

by Kinjel Shah

The FDA approves Novartis' (NVS) sickle cell disease candidate Adakveo and AstraZeneca's (AZN) Calquence for chronic lymphocytic leukemia. Bristol-Myers (BMY) completes $74 billion-buyout of Celgene.

Medicines Company Up on Rumors of Potential Buyout by Novartis

by Zacks Equity Research

The Medicines Company (MDCO) is rumored to attract acquisition offers after impressive data readouts from three pivotal studies on PCSK9 inhibitor candidate, inclisiran.

Merck's Heart Failure Candidate Meets Goal in Phase III Study

by Zacks Equity Research

Merck (MRK) and German partner Bayer's vericiguat reduces the risk of heart failure hospitalization or cardiovascular death in patients with worsening chronic heart failure.

Aerie to Acquire Dry Eye Disease-Focused Pharma Avizorex

by Zacks Equity Research

Aerie (AERI) will acquire Spanish ophthalmic pharmaceutical company, Avizorex Pharma, to add a mid-stage dry eye disease candidate to its pipeline.

Novartis Receives FDA Nod for Adakveo in Sickle Cell Disease

by Zacks Equity Research

Novartis (NVS) gets FDA nod for Adakveo to reduce the frequency of pain crises in adult and pediatric SCD patients.

Jazz's (JAZZ) Sleep Drug Sunosi Nears Approval in Europe

by Zacks Equity Research

Jazz's (JAZZ) sleep drug, Sunosi, which is under review in Europe, receives recommendation for approval from the CHMP.

The Zacks Analyst Blog Highlights: Microsoft, Novartis, Novo Nordisk, Tesla and General Dynamics

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Microsoft, Novartis, Novo Nordisk, Tesla and General Dynamics

Mark Vickery headshot

Top Analyst Reports for Microsoft, Novartis & Novo Nordisk

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), Novartis (NVS) and Novo Nordisk (NVO).

Roche's SMA Drug Meets Primary Endpoint in Pivotal Study

by Zacks Equity Research

Roche's (RHHBY) risdiplam meets primary endpoint in SUNFISH study in SMA patients.

The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Novo Nordisk, Allergan, Sanofi, Novartis and J&J

Chegg, C.H. Robinson Worldwide, Tilray, Anheuser-Busch InBev and Novartis highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Chegg, C.H. Robinson Worldwide, Tilray, Anheuser-Busch InBev and Novartis highlighted as Zacks Bull and Bear of the Day

Novartis' Generics Unit to Buy Aspen's Japanese Operations

by Zacks Equity Research

Novartis (NVS) inks a deal to acquire the Japanese business of Aspen Global Incorporated.

Christopher Vargas headshot

Tilray (TLRY) Set to Report Q3 Results: Will the Stock Continue to Plunge?

by Christopher Vargas

Tilray (TLRY) is set to report its third quarter results after the closing bell Tuesday, November 12.

Aduro (ADRO) Q3 Loss Wider Than Expected, Revenues Rise Y/Y

by Zacks Equity Research

Aduro's (ADRO) loss misses estimates in Q3 while revenues almost match the mark.

Kinjel Shah headshot

Pharma Stock Roundup: AGN, NVO Q3 Earnings, FDA Nod to SNY & NVS' Products

by Kinjel Shah

Novo Nordisk (NVO) and Allergan (AGN) release Q3 results. FDA approves Sanofi's quadrivalent flu vaccine for older adults and Novartis' long-acting biosimilar version of Amgen's Neulasta.

Puma (PBYI) Q3 Earnings Beat, Nerlynx Sales Weak, Stock Down

by Zacks Equity Research

Puma Biotech (PBYI) incurs narrower loss in Q3. Sales of Nerlynx decline sequentially. Stock drops 18%.